Nephron Researc Comments on Elevance Health Q2 Earnings

Elevance Health, Inc. (NYSE:ELV) – Analysts at Nephron Researc issued their Q2 2026 earnings per share (EPS) estimates for Elevance Health in a report issued on Wednesday, June 24th. Nephron Researc analyst E. Percher anticipates that the company will post earnings of $6.15 per share for the quarter. The consensus estimate for Elevance Health’s current full-year earnings is $26.86 per share. Nephron Researc also issued estimates for Elevance Health’s Q3 2026 earnings at $4.96 EPS, Q4 2026 earnings at $3.06 EPS, FY2026 earnings at $25.73 EPS, Q1 2027 earnings at $13.01 EPS, Q2 2027 earnings at $6.74 EPS, Q3 2027 earnings at $5.53 EPS, Q4 2027 earnings at $3.56 EPS and FY2027 earnings at $28.95 EPS.

Elevance Health (NYSE:ELV) last announced its quarterly earnings data on Wednesday, April 22nd. The company reported $12.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $10.74 by $1.84. Elevance Health had a return on equity of 15.58% and a net margin of 2.62%.The firm had revenue of $49.49 billion for the quarter, compared to analysts’ expectations of $48.21 billion. During the same quarter in the prior year, the firm posted $11.97 earnings per share. Elevance Health’s revenue for the quarter was up 1.5% compared to the same quarter last year. Elevance Health has set its FY 2026 guidance at 19.850- EPS.

Other equities analysts have also recently issued reports about the company. Jefferies Financial Group reduced their price objective on Elevance Health from $395.00 to $391.00 and set a “buy” rating on the stock in a research note on Monday, April 20th. Truist Financial boosted their target price on shares of Elevance Health from $375.00 to $450.00 and gave the company a “buy” rating in a research note on Monday, June 1st. Morgan Stanley increased their target price on shares of Elevance Health from $352.00 to $404.00 and gave the stock an “equal weight” rating in a report on Thursday, June 4th. The Goldman Sachs Group raised their price target on shares of Elevance Health from $350.00 to $370.00 and gave the stock a “neutral” rating in a research report on Friday, April 24th. Finally, Guggenheim lifted their price target on shares of Elevance Health from $396.00 to $399.00 and gave the company a “buy” rating in a report on Friday, April 24th. Fourteen research analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $416.11.

Elevance Health Price Performance

Shares of NYSE ELV opened at $394.86 on Monday. Elevance Health has a twelve month low of $273.71 and a twelve month high of $426.98. The company has a current ratio of 1.48, a quick ratio of 1.48 and a debt-to-equity ratio of 0.70. The company has a market capitalization of $85.75 billion, a price-to-earnings ratio of 16.80, a price-to-earnings-growth ratio of 2.24 and a beta of 0.67. The business has a 50 day simple moving average of $383.03 and a 200-day simple moving average of $349.14.

Hedge Funds Weigh In On Elevance Health

Several hedge funds and other institutional investors have recently modified their holdings of ELV. Kemnay Advisory Services Inc. acquired a new stake in shares of Elevance Health in the 4th quarter worth about $31,000. J.Safra Asset Management Corp acquired a new position in Elevance Health during the 4th quarter valued at about $32,000. WealthCollab LLC boosted its stake in Elevance Health by 42.2% during the 1st quarter. WealthCollab LLC now owns 91 shares of the company’s stock valued at $27,000 after purchasing an additional 27 shares during the period. ORG Partners LLC grew its position in Elevance Health by 120.4% in the 4th quarter. ORG Partners LLC now owns 108 shares of the company’s stock worth $38,000 after purchasing an additional 59 shares during the last quarter. Finally, Dorato Capital Management bought a new position in Elevance Health in the 4th quarter worth about $41,000. Institutional investors and hedge funds own 89.24% of the company’s stock.

Insiders Place Their Bets

In other Elevance Health news, Director Robert L. Dixon, Jr. sold 151 shares of the stock in a transaction on Thursday, June 11th. The stock was sold at an average price of $401.77, for a total value of $60,667.27. Following the sale, the director directly owned 10,734 shares of the company’s stock, valued at $4,312,599.18. This trade represents a 1.39% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 0.34% of the stock is owned by corporate insiders.

Elevance Health Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Thursday, June 25th. Investors of record on Wednesday, June 10th were paid a dividend of $1.72 per share. This represents a $6.88 dividend on an annualized basis and a yield of 1.7%. The ex-dividend date was Wednesday, June 10th. Elevance Health’s dividend payout ratio is presently 29.26%.

Key Elevance Health News

Here are the key news stories impacting Elevance Health this week:

• Positive Sentiment: Nephron Research’s FY2027 EPS estimate of $28.95 is above the current consensus, signaling stronger expected earnings growth ahead.
• Positive Sentiment: The firm also projected FY2026 EPS of $25.73, which supports a solid near-term earnings profile for Elevance Health.
• Neutral Sentiment: Nephron Research provided quarterly estimates across 2026 and 2027, including Q2 2026 EPS of $6.15 and Q1 2027 EPS of $13.01, but the release was primarily an estimates update rather than a new business announcement.
• Neutral Sentiment: An article previewing Elevance Health’s Q2 2026 earnings suggests investors are positioning ahead of the next report, but no actual results were released in these items.

About Elevance Health

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.